At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,927 enrolled
Drug / intervention
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live +2 morebiological
Likely dose
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children
In Brief
A Phase 3 clinical trial evaluating Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, and 1 other intervention for Measles and 3 related conditions. Completed, enrolled 3,927 participants.
Detailed Summary
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.
Study Details
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2000
Primary CompletionMay 2001
First PostedSep 2009
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartMar 1, 2000
Primary CompletionMay 1, 2001
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.8 years ago
Interventions
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Livebiological
A Single 0.5 mL subcutaneous injection at Day 0
Comparator: Varivaxbiological
A Single 0.5 mL subcutaneous injection at Day 0
Comparator: M-M-R IIbiological
A Single 0.5 mL subcutaneous injection at Day 0